Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
» SNTS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

SNTS Guru Trades in Q2 2013

Jim Simons 2,684,843 sh (+5.33%)
Paul Tudor Jones 11,600 sh (-1.69%)
Steven Cohen 10,940 sh (-68.37%)
» More
Q3 2013

SNTS Guru Trades in Q3 2013

Joel Greenblatt 66,922 sh (New)
Steven Cohen 79,817 sh (+629.59%)
Paul Tudor Jones 23,000 sh (+98.28%)
Jim Simons 2,142,938 sh (-20.18%)
» More
Q4 2013

SNTS Guru Trades in Q4 2013

Mario Gabelli 392,700 sh (New)
John Paulson 5,000,000 sh (New)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 2,136,038 sh (-0.32%)
Joel Greenblatt 25,257 sh (-62.26%)
» More
Q1 2014

SNTS Guru Trades in Q1 2014

John Paulson Sold Out
Mario Gabelli Sold Out
Joel Greenblatt Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SNTS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-03-31 Sold Out 0.79%$31.96 - $31.97 $ 31.960%0
Mario Gabelli 2014-03-31 Sold Out 0.07%$31.96 - $31.97 $ 31.960%0
Joel Greenblatt 2014-03-31 Sold Out 0.02%$31.96 - $31.97 $ 31.960%0
John Paulson 2013-12-31 New Buy0.79%$21.05 - $32.18 $ 31.9614%5000000
Mario Gabelli 2013-12-31 New Buy0.07%$21.05 - $32.18 $ 31.9614%392700
Joel Greenblatt 2013-12-31 Reduce -62.26%0.03%$21.05 - $32.18 $ 31.9614%25257
Joel Greenblatt 2013-09-30 New Buy0.05%$21.17 - $27.26 $ 31.9634%66922
George Soros 2011-09-30 Sold Out 0.0013%$2.49 - $3.39 $ 31.96941%0
George Soros 2011-06-30 Add 46.35%$3.03 - $3.48 $ 31.96892%28100
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Santarus, Inc.

Mario Gabelli Comments on Valassis Communications - Apr 30, 2014

Valassis Communications Inc. (VCI) is a Michigan based media and advertising company specializing in direct marketing services. On December 18, 2013, the company received a $34.04 cash tender offer from Harland Clarke Holdings Corp., a private marketing and integrated payment solutions provider located in San Antonio, Texas. The deal closed in early February after receiving the necessary minimum condition and regulatory approvals. The Fund earned a 4.18% return.

From Mario Gabelli (Trades, Portfolio)'s first quarter 2014 ABC Fund commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Santarus, Inc.

Ratios

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TW4A.Germany
Santarus, Inc. was incorporated on December 6, 1996 as a California corporation and did not commence significant business activities until late 1998. On July 9, 2002, the Company reincorporated in the State of Delaware. The Company is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. It sells brand prescription products primarily to pharmaceutical wholesalers, who in turn seek to distribute the products to retail pharmacies, mail order pharmacies, hospitals and other institutional customers. The Company's current commercial efforts are focused on five products: UCERIS, extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists; GLUMETZA and CYCLOSET tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; and FENOGLIDE tablets, which is indicated as an adjunct to diet to reduce high cholesterol. The pipeline products include the investigational drug RUCONEST for treatment of acute attacks of hereditary angioedema.
» More Articles for SNTS

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on Valassis Communications Apr 30 2014 
Mario Gabelli Comments on Santarus Inc. Apr 30 2014 
Mario Gabelli's ABC Fund First Quarter 2014 Letter Apr 30 2014 
Mario Gabelli’s Top 5 Fourth-Quarter Stock Buys Feb 07 2014 
comment on SNTS Mar 06 2013 
comment on SNTS Mar 02 2013 
Santarus Inc. Reports Operating Results (10-K) Mar 04 2011 
Santarus Inc. Reports Operating Results (10-Q) Nov 09 2010 
Santarus Inc. Reports Operating Results (10-Q) Aug 03 2010 
Santarus Inc. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
Salix Pharmaceuticals Completes Acquisition of Santarus Jan 02 2014
SANTARUS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a... Jan 02 2014
RedHill Biopharma Sells ADS Dec 31 2013
Pipeline Setback at Can-Fite BioPharma, Shares Down Dec 31 2013
Santarus Announces Availability of Amended Tender Offer Materials Dec 30 2013
Santarus Announces Availability of Amended Tender Offer Materials Dec 30 2013
Durata Progresses with Dalbavancin Dec 27 2013
Pipeline Update on Aratana Dec 27 2013
Update on MDCO's Pipeline Dec 27 2013
Pipeline Update on Santarus Candidate Dec 26 2013
Update on ARIAD's Iclusig Dec 26 2013
G-III Apparel Group Set to Join the S&P SmallCap 600 Dec 23 2013
Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis Dec 23 2013
Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis Dec 23 2013
Salix Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of... Dec 10 2013
Leveraged Loan Volume Surges To $21B As Issuers Race to Year-End Dec 06 2013
Salix Pharmaceuticals Commences Cash Tender Offer for All Outstanding Shares of Santarus Dec 03 2013
Santarus: To Hold Or Take Profits Now? Nov 16 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide